In Vivo Delivery for Gene Therapy

In vivo delivery for gene therapy refers to the direct administration of genetic material into a patient’s body to modify, replace, or regulate gene expression within target cells. Unlike ex vivo approaches, where cells are modified outside the body and reinfused, in vivo strategies rely on delivery vectors to navigate biological barriers, achieve cellular uptake, and ensure functional gene expression at the disease site. Common vectors used in in vivo gene delivery systems include viral systems such as Adeno-associated virus (AAV), Lentivirus, and Adenovirus, as well as non-viral platforms like lipid nanoparticles. These systems are engineered for tissue specificity, minimized immunogenicity, and efficient transduction. In vivo delivery is central to treating genetic disorders, cancers, and infectious diseases, offering the potential for long-term or permanent therapeutic effects through a single administration.

The success of in vivo gene therapy hinges on overcoming multiple physiological and molecular barriers. After systemic or localized administration, vectors must evade immune detection, maintain stability in circulation, and selectively accumulate in target tissues. For example, AAV vectors are widely used due to their low pathogenicity and ability to transduce non-dividing cells, but they are constrained by limited cargo capacity and pre-existing immunity in some patients. In contrast, non-viral systems such as lipid nanoparticles famously utilized in mRNA vaccines offer scalable manufacturing and reduced immunogenic risk, though often with lower delivery efficiency.

Targeting specificity is achieved through capsid engineering, ligand modification, or tissue-specific promoters, enabling precision medicine applications. Diseases such as Spinal muscular atrophy and Hemophilia have seen transformative therapies using in vivo delivery platforms. Additionally, genome editing tools like CRISPR-Cas9 are increasingly integrated into delivery systems to enable permanent correction of disease-causing mutations.

However, challenges remain, including off-target effects, dose-dependent toxicity, and regulatory complexity. Long-term safety monitoring is essential, particularly for integrating vectors. Advances in synthetic biology, vector design, and delivery engineering continue to refine in vivo approaches, positioning them as a cornerstone of next-generation therapeutics.

Mechanisms of gene transfer and cellular entry

A central feature of in vivo gene therapy is the use of transduction as the primary mechanism for introducing therapeutic genetic material into host cells. In this context, viral vectors such as Adeno-associated virus, Adenovirus, and Lentivirus are engineered to act as delivery vehicles. These vectors exploit the natural biological ability of viruses to penetrate host cells and deposit genetic material into the intracellular environment.

Once administered, the vector must successfully navigate several biological barriers, including circulatory degradation, immune surveillance, and cell membrane penetration. Upon reaching the target cell, the vector binds to specific cell surface receptors, facilitating entry via endocytosis or membrane fusion. The delivered genetic material is then released into the cytoplasm and, depending on the vector type, may enter the nucleus for gene expression or genomic integration.

The specificity of this process is enhanced through capsid engineering and promoter design, allowing vectors to preferentially target certain tissues while minimizing off-target effects. This level of control is critical for improving both therapeutic efficacy and biosafety.

Target tissues and physiological considerations

In vivo delivery systems are designed to reach a wide range of target tissues, including the brain, liver, lungs, muscle, and vascular endothelium. Each tissue presents unique physiological challenges. For instance, delivery to the brain requires crossing the blood-brain barrier, while hepatic delivery must account for rapid uptake and clearance by liver cells.

The liver is one of the most commonly targeted organs due to its high vascularization and metabolic activity, making it an ideal site for treating systemic genetic disorders. Similarly, muscle tissue is frequently targeted for its accessibility and capacity for sustained gene expression. In contrast, targeting the central nervous system requires highly specialized vectors capable of penetrating protective barriers without inducing inflammation.

Effective targeting is often achieved through localized delivery methods, including direct injection or catheter-based administration. These approaches enable clinicians to concentrate the therapeutic agent at the disease site, thereby reducing systemic exposure and potential toxicity.

Delivery techniques and clinical implementation

The success of in vivo gene delivery depends heavily on the method of administration. Catheterization techniques, often guided by imaging technologies such as fluoroscopy or magnetic resonance imaging (MRI), allow for precise delivery into specific organs or vascular compartments. These minimally invasive procedures are widely used in cardiovascular and hepatic gene therapy applications.

In addition to surgical approaches, systemic delivery through intravenous injection is also common, particularly when targeting widespread tissues (Figure 1). However, systemic administration requires careful optimization of vector dose, circulation time, and immune evasion strategies.

Emerging technologies now incorporate computer-assisted navigation systems and real-time imaging, enhancing the precision of gene delivery. These advancements are particularly important for complex anatomical targets, where accurate localization determines therapeutic success.

Advantages of viral vectors in in vivo systems

Among all delivery systems, viral vectors remain the most efficient tools for in vivo gene therapy. Their superiority stems from their evolutionary adaptation to infect host cells and deliver genetic material with high efficiency. This intrinsic capability gives them a significant advantage over non-viral alternatives.

Engineered viral vectors are typically attenuated, meaning they have been modified to remove their pathogenic properties while retaining their delivery efficiency. This ensures that they do not cause disease while still performing their role as gene carriers.

For example, AAV vectors are particularly valued for their low immunogenicity and ability to achieve long-term gene expression in non-dividing cells. Lentiviral vectors, on the other hand, are capable of integrating into the host genome, enabling stable, long-term expression of therapeutic genes. Adenoviral vectors offer high transduction efficiency but may elicit stronger immune responses, necessitating careful clinical management.

Role of non-viral delivery systems in in vivo gene therapy

While viral vectors dominate the field, non-viral delivery systems are gaining increasing attention. Technologies such as lipid nanoparticles, widely used in mRNA vaccines, provide a safer and more scalable alternative. These systems encapsulate genetic material and facilitate its delivery into cells without using viral components.

Non-viral approaches offer advantages such as reduced immunogenicity, ease of manufacturing, and larger cargo capacity. However, they often face challenges related to lower delivery efficiency and transient gene expression. Ongoing research focuses on improving their targeting capabilities and stability within biological systems.

Precision and targeting strategies in in vivo gene therapy

A major advancement in in vivo gene therapy is the development of precision targeting strategies. These include ligand-receptor interactions, tissue-specific promoters, and genetic regulatory elements that restrict gene expression to desired cell types. The integration of genome editing technologies such as CRISPR-Cas9 has further enhanced the precision of in vivo approaches. Instead of simply adding a functional gene, these systems enable direct correction of genetic mutations at their source.

This represents a shift from gene supplementation to genome editing, offering the potential for permanent cures. CRISPR-Cas stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins. CRISPR is a powerful biotechnology tool that enables scientists to precisely edit or modify an organism’s DNA by adding, removing, or altering genetic material at specific locations. Originally derived from a natural defense mechanism that bacteria use to protect themselves against viruses, CRISPR functions like molecular scissors, enabling precise and targeted modifications of specific genes.

Clinical applications and therapeutic impact of in vivo gene therapy

In vivo gene therapy has demonstrated remarkable success in treating a variety of genetic and acquired diseases. Conditions such as Spinal muscular atrophy and Hemophilia have been effectively managed using targeted gene delivery strategies.

In oncology, in vivo approaches are being explored to deliver genes that enhance immune responses against tumors or directly induce cancer cell death. Similarly, infectious diseases and metabolic disorders are emerging targets for gene-based interventions.

The ability to achieve long-term or even permanent therapeutic effects with a single administration makes in vivo gene therapy a transformative modality in modern medicine.

Viral vectors in in vivo gene therapy

Viral vectors are the most extensively utilized tools for in vivo gene therapy delivery, owing to their natural ability to enter host cells and efficiently transfer genetic material. In therapeutic applications, these viruses are genetically engineered to remove virulence factors, rendering them apathogenic while preserving their delivery efficiency. Once modified, they function as carriers of therapeutic DNA, which can be administered either intravenously for systemic distribution or locally injected into specific tissues. Following administration, these vectors target host cells, deliver the gene of interest, and enable the production of functional proteins or enzymes necessary to correct genetic defects.

Adenoviruses (adenoviral vectors)

Adenovirus vectors are among the earliest and most well-characterized systems used in in vivo gene therapy. They are double-stranded DNA viruses capable of infecting a wide range of dividing and non-dividing cells, making them highly versatile for therapeutic applications. One of their key advantages is their high transduction efficiency, which allows rapid and robust expression of the delivered gene. This makes adenoviral vectors particularly useful in applications such as cancer gene therapy, where strong but often transient gene expression is desirable.

Another important feature of adenoviruses is their relatively large genetic payload capacity, enabling the delivery of sizable or multiple therapeutic genes. However, they typically do not integrate into the host genome; instead, the delivered DNA remains episomal, resulting in temporary gene expression. While this reduces the risk of insertional mutagenesis, it also necessitates repeated administration in some cases.

A major limitation of adenoviral vectors is their tendency to provoke strong immune responses, which can lead to inflammation, reduced therapeutic efficacy, and potential toxicity. Pre-existing immunity in patients further complicates their clinical use. As a result, current research focuses on modifying adenoviral capsids and improving delivery strategies to enhance safety and reduce immunogenicity.

Retroviruses (retroviral vectors)

Retrovirus vectors are RNA viruses that have the unique ability to integrate their genetic material into the host genome. This feature makes them particularly valuable for achieving long-term and stable gene expression, especially in rapidly dividing cells. After entering the host cell, the viral RNA is reverse-transcribed into DNA and then integrated into the host’s chromosomal DNA, ensuring that the therapeutic gene is replicated along with the cell’s genome during cell division.

This property has made retroviral vectors highly useful in treating genetic disorders that require permanent correction, such as certain blood and immune system diseases. However, their integration into the genome presents a significant risk known as insertional mutagenesis, where the integration event may disrupt essential genes or activate oncogenes, potentially leading to cancer.

Additionally, traditional retroviruses primarily infect dividing cells, limiting their effectiveness in tissues composed largely of non-dividing cells, such as neurons. Advances in vector design, including the development of lentiviral systems, have partially addressed this limitation. Despite these improvements, safety concerns related to genomic integration remain a critical consideration in their clinical application.

Adeno-associated viruses (AAVs)

Adeno-associated virus vectors are currently among the most widely used and promising systems in in vivo gene therapy. These are small, single-stranded DNA viruses that are not known to cause disease in humans, making them particularly attractive from a safety perspective. AAV vectors are capable of infecting both dividing and non-dividing cells and are especially effective in targeting tissues such as the liver, muscle, and central nervous system.

One of the defining characteristics of AAV vectors is their ability to provide long-term gene expression with minimal immune activation compared to other viral systems. In most cases, AAV-delivered genes remain episomal, reducing the risk of insertional mutagenesis while still achieving sustained therapeutic effects.

However, AAV vectors have a relatively limited cargo capacity, restricting the size of genes they can deliver. Additionally, pre-existing immunity to AAV in some individuals can reduce transduction efficiency. Despite these challenges, AAV-based therapies have shown remarkable success in treating diseases such as Spinal muscular atrophy and Hemophilia, highlighting their clinical potential.

Balancing efficiency and safety in viral in vivo gene delivery

In in vivo gene therapy, viral vectors are deliberately engineered to enhance safety while preserving their natural delivery efficiency. This is achieved by modifying or removing virulence-associated genes, thereby rendering the viruses apathogenic and suitable for therapeutic use. Once engineered, these vectors serve as highly specialized carriers of therapeutic DNA, which can be administered either systemically (intravenously) or through localized injection into a specific tissue. Following administration, the vectors are taken up by target cells, where they release the genetic material, enabling the cells to synthesize functional proteins or enzymes that can correct underlying genetic defects or restore normal physiological function.

Despite these advantages, the clinical application of viral vectors is not without limitations. A key concern is the potential for unexpected immune responses, as the host immune system may recognize the viral particles as foreign, leading to inflammation or reduced therapeutic efficacy. In some cases, even attenuated vectors such as Adenovirus or Adeno-associated virus may trigger immune activation, particularly in individuals with pre-existing immunity.

Additionally, there remains a theoretical risk that modified viruses could regain pathogenic characteristics through recombination or unintended genetic interactions within the host. Other safety concerns include off-target effects, dose-dependent toxicity, and, in the case of integrating vectors, the possibility of insertional mutagenesis. These factors collectively underscore the importance of rigorous vector design, careful dose optimization, and long-term patient monitoring. While viral vectors remain the most efficient tools for in vivo gene delivery, ongoing research is essential to further improve their safety, specificity, and clinical reliability, ensuring that their therapeutic potential can be fully realized with minimal risk.

References

Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022). Gene therapy: Comprehensive overview and therapeutic applications. Life Sciences, 294, 120375. 

Rashid, R. A., & Ankathil, R. (2020). Gene therapy: An updated overview on the promising success stories. Malaysian Journal of Pathology, 42(2), 171–185.

Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts Kand Walter P (1998). Essential Cell Biology: An Introduction to the Molecular Biology of the Cell. Third edition. Garland Publishing Inc., New York.

Dale J (2003). Molecular genetics of bacteria. Jeremy W. Dale and Simon Park (4^th eds.). John Wiley & Sons Ltd, West Sussex, UK.

Edelstein, M. L., Abedi, M. R., Wixon, J., and Edelstein, R. M. (2004). Gene therapy clinical trials worldwide 1989-2004—an overview. J Gene Med, 6: 597-602.

Ferrua, F.; Brigida, I.; Aiuti, A. (2010). Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Current Opinion in Allergy and Clinical Immunology. 10 (6): 551–556.

Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P; Pálffy; Hodosy; Lukács; Turna; Celec (2005). Vectors and delivery systems in gene therapy. Med Sci Monit. 11 (4): RA110–21.

Horn PA, Morris JC, Neff T, Kiem HP; Morris; Neff; Kiem (2004). Stem cell gene transfer—efficacy and safety in large animal studies. Mol. Ther. 10 (3): 417–31.

S Li and L Huang (2000). Nonviral gene therapy: promises and challenges. Gene Therapy, 7:31-34. www.nature.com/gt

Salmons B, Günzburg WH; Günzburg (1993). Targeting of retroviral vectors for gene therapy. Hum Gene Ther. 4 (2): 129–41.

Sambrook, J., Russell, D.W. (2001). Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press, New York.

Sheridan C (2011). Gene therapy finds its niche. Nature Biotechnology. 29 (2): 121–128.

Vannucci, L; Lai, M; Chiuppesi, F; Ceccherini-Nelli, L; Pistello, M (2013). Viral vectors: A look back and ahead on gene transfer technology. The new microbiologica. 36 (1): 1–22.